Lv11
70 积分 2022-10-20 加入
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
2小时前
待确认
靶向TROP2的抗体药物偶联物应用于非小细胞肺癌的专家共识（2026版）
22天前
已完结
Lung cancer in women: current evidence and future research priorities
1个月前
已关闭
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer
2个月前
已完结
Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC
2个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
4个月前
已完结
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
4个月前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
5个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
5个月前
已完结
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
5个月前
已完结
皖公网安备34019202002308
